» Articles » PMID: 15069806

Five-year Relative Survival from Prostate, Breast, Colorectal and Lung Cancer

Overview
Journal Health Rep
Specialty Public Health
Date 2004 Apr 9
PMID 15069806
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: This article presents five-year relative survival rates for prostate, breast, colorectal and lung cancer diagnosed in 1992. Provincial variations are also examined.

Data Sources: Data are from the Canadian Cancer Registry, the National Cancer Incidence Reporting System, the Canadian Mortality Data Base, and life tables.

Analytical Techniques: Analysis was conducted using the maximum likelihood method of Estève. Provincial rates were standardized to the age distribution of patients diagnosed with the specific cancer. Statistical tests were conducted to determine if the site-specific age-standardized provincial relative survival rates should be regarded as heterogeneous. (National estimates exclude Québec.)

Main Results: Five-year relative survival rates for ages 15 to 99 were highest for prostate cancer (88%) and lowest for lung cancer (17%, women; 14%, men). Relative survival rates for prostate, breast and male lung cancer differ among provinces. There was little inter-provincial variation in relative survival rates for colorectal cancer.

Citing Articles

Trends in 5-year cancer survival disparities by race and ethnicity in the US between 2002-2006 and 2015-2019.

Chen C, Yin L, Lu C, Wang G, Li Z, Sun F Sci Rep. 2024; 14(1):22715.

PMID: 39349542 PMC: 11442861. DOI: 10.1038/s41598-024-73617-z.


Differences in cancer survival by area-level socio-economic disadvantage: A population-based study using cancer registry data.

Afshar N, English D, Blakely T, Thursfield V, Farrugia H, Giles G PLoS One. 2020; 15(1):e0228551.

PMID: 31999795 PMC: 6992207. DOI: 10.1371/journal.pone.0228551.


Cancer incidence and survival among Métis adults in Canada: results from the Canadian census follow-up cohort (1992-2009).

Mazereeuw M, Withrow D, Nishri E, Tjepkema M, Vides E, Marrett L CMAJ. 2018; 190(11):E320-E326.

PMID: 29555862 PMC: 5860893. DOI: 10.1503/cmaj.170272.


Canadian brain cancer survival rates by tumour type and region: 1992-2008.

Yuan Y, Shi Q, Li M, Nagamuthu C, Andres E, Davis F Can J Public Health. 2016; 107(1):e37-e42.

PMID: 27348108 PMC: 6972338. DOI: 10.17269/cjph.107.5209.


Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells.

Cao W, Liu Y, Zhang R, Zhang B, Wang T, Zhu X Sci Rep. 2015; 5:8477.

PMID: 26166037 PMC: 4499885. DOI: 10.1038/srep08477.